Epidemiology and Effects of Substance Use in Pregnancy

Journal of Obstetrics and Gynaecology Canada

Volumn 39, Issue 10, 2017, Pages 906-915

  Cook, Jocelynn L ^a,b   Green, Courtney R ^b   de la Ronde, Sandra ^c   Dell, Colleen A ^d   Graves, Lisa ^e   Ordean, Alice ^f   Ruiter, James ^g   Steeves, Megan ^d   Wong, Suzanne ^h  

^a UNIVERSITY OF OTTAWA   (Canada)

^b The Society of Obstetricians and Gynaecologists of Canada   (United States)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e WESTERN MICHIGAN UNIVERSITY HOMER STRYKER MD SCHOOL OF MEDICINE   (United States)

^f ST JOSEPH S HEALTH CENTRE   (Canada)

^g Salus Global Corporation   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

cannabis; hallucinogens; opioids; pregnancy; stimulants; Substance use

Indexed keywords

ALCOHOL; AMPHETAMINE; CANNABIS; COCAINE; ILLICIT DRUG; OPIATE;

ALCOHOL ABUSE; AMPHETAMINE DEPENDENCE; CANADA; CANNABIS ADDICTION; COCAINE DEPENDENCE; DRUG DEPENDENCE; GEOGRAPHIC DISTRIBUTION; HUMAN; MATERNAL SMOKING; NEUROBIOLOGY; OPIATE ADDICTION; PREGNANCY; PREGNANCY OUTCOME; PREVALENCE; REVIEW; RISK FACTOR; SMOKING CESSATION; SUBSTANCE ABUSE; SUBSTANCE USE; TERATOGENICITY; UNITED STATES; COMPLICATION; FEMALE; PREGNANCY COMPLICATION;

FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; SUBSTANCE-RELATED DISORDERS;

EID: 85029482532     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jogc.2017.07.005     Document Type: Review

References (88)

1. World Health Organization, Substance use. 2017, WHO., Geneva, Switzerland Available at: http://www.who.int/topics/substance_abuse/en/, Accessed date 31 July 2017.
2. American Psychiatric Association, Diagnostic and statistical manual of mental disorders. 5th ed., 2013, American Psychiatric Association Publishing, Arlington, VA.
3. Managing obstetrical risk efficiently (MOREOB), Salus Global; Available at: http://moreob.com/, Accessed date 1 September 2017.
4. Kaplan, G.B., Hammer, R.P., Brain circuitry and signaling in psychiatry: basic science and clinical implications. 2002, American Psychiatric Association Publishing, Arlington, VA.
5. Centers for Disease Control and Prevention, Adverse childhood experiences (ACEs). 2016, Centers for Disease Control and Prevention, Atlanta, GA Available at: https://www.cdc.gov/violenceprevention/acestudy/index.html, Accessed date 31 July 2017.
6. Sternberg, E.M., Chrousos, G.P., Wilder, R.L., et al. The stress response and the regulation of inflammatory disease. Ann Intern Med 117 (1992), 854–866.
7. Waffarn, F., Davis, E.P., Effects of antenatal corticosteroids on the hypothalamic-pituitary-adrenocortical axis of the fetus and newborn: experimental findings and clinical considerations. Am J Obstet Gynecol 207 (2012), 446–454.
8. United States Department of Health, Human Services, Substance Abuse, Mental Health Services Administration. Center for Behavioral Health Statistics and Quality: National Survey on Drug Use and Health, 2012. Inter-university Consortium for Political and Social Research (ICPSR) [distributor]. 2013.
9. Health Canada, Canadian alcohol and drug use monitoring survey. 2014, Health Canada, Ottawa Available at: https://www.canada.ca/en/health-canada/services/health-concerns/drug-prevention-treatment/canadian-alcohol-drug-use-monitoring-survey.html, Accessed date 31 July 2017.
10. Stinson, F.S., Grant, B.F., Dawson, D.A., et al. Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 80 (2005), 105–116.
11. Steingrimsson, S., Carlsen, H.K., Sigfusson, S., et al. The changing gender gap in substance use disorder: a total population-based study of psychiatric in-patients. Addiction 107 (2012), 1957–1962.
12. Keyes, K.M., Grant, B.F., Hasin, D.S., Evidence for a closing gender gap in alcohol use, abuse, and dependence in the United States population. Drug Alcohol Depend 93 (2008), 21–29.
13. Compton, W.M., Thomas, Y.F., Stinson, F.S., et al. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 64 (2007), 566–576.
14. Ebrahim, S.H., Gfroerer, J., Pregnancy-related substance use in the United States during 1996–1998. Obstet Gynecol 101 (2003), 374–379.
15. Finnegan, L., Substance abuse in Canada. Licit and illicit drug use during pregnancy: maternal, neonatal and ealry childhood consequences. 2013, Canadian Centre on Substance Abuse, Ottawa Available at: http://www.ccsa.ca/Resource%20Library/CCSA-Drug-Use-during-Pregnancy-Report-2013-en.pdf, Accessed date 31 July 2017.
16. Howell, E.M., Heiser, N., Harrington, M., A review of recent findings on substance abuse treatment for pregnant women. J Subst Abuse Treat 16 (1999), 195–219.
17. Crome, I.B., Ismail, K.M.K., Birnbach, D., Substance misuse in pregnancy. Powrie, M.F., Greene, M.F., Camann, W., (eds.) de Swiet's medical disorders in obstetric practice, 2010, Wiley-Blackwell, West Sussex, UK, 477–504.
18. Crome, I.B., Kumar, M.T., Epidemiology of drug and alcohol use in young women. Semin Fetal Neonatal Med 12 (2007), 98–105.
19. National Treatment Agency for Substance Misuse, Department of Health [DoH], Models of care for substance misuse treatment. London, UK, 2002 0-9544534-0-9 http://www.nta.nhs.uk/uploads/nta_modelsofcare2_2002_moc2.pdf, Accessed date 1 September 2017.
20. Center for Behavioral Health Statistics and Quality, Substance use during pregnancy varies by race and ethnicity. 2012, Substance Abuse and Mental Health Services Administration, Rockville, MD Available at: https://www.samhsa.gov/data/sites/default/files/Spot062PregnantRaceEthnicity2012/Spot062PregnantRaceEthnicity2012.pdf, Accessed date 31 July 2017.
21. Forray, A., Foster, D., Substance use in the perinatal period. Curr Psychiatry Rep, 17, 2015, 91.
22. Public Health Agency of Canada, What mothers say: the Canadian maternity experiences survey. 2009, Public Health Agency of Canada, Ottawa Available at: http://www.phac-aspc.gc.ca/rhs-ssg/survey-eng.php, Accessed date 31 July 2017.
23. Public Health Agency of Canada, Perinatal health indicators for Canada 2013: a report of the Canadian perinatal surveillance system. 2013, Public Health Agency of Canada, Ottawa Available at: http://publications.gc.ca/collections/collection_2014/aspc-phac/HP7-1-2013-eng.pdf, Accessed date 31 July 2017.
24. Substance Abuse and Mental Health Services Administration, Results from the 2010 national survey on drug use and health: summary of national findings. 2011, Substance Abuse and Mental Health Services Administration, Rockville, MD Available at: https://www.samhsa.gov/data/sites/default/files/NSDUHNationalFindingsResults2010-web/2k10ResultsRev/NSDUHresultsRev2010.pdf, Accessed date 31 July 2017.
25. Substance Abuse and Mental Health Services Administration, The NSDUH report: substance use among women during pregnancy and following childbirth. 2009, Substance Abuse and Mental Health Services Administration, Rockville, MD Available at: http://archive.samhsa.gov/data/2k9/135/PregWoSubUse.htm, Accessed date 31 July 2017.
26. Hayes, M.J., Brown, M.S., Epidemic of prescription opiate abuse and neonatal abstinence. JAMA 307 (2012), 1974–1975.
27. Desai, R.J., Hernandez-Diaz, S., Bateman, B.T., et al. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol 123 (2014), 997–1002.
28. Ailes, E.C., Dawson, A.L., Lind, J.N., et al. Opioid prescription claims among women of reproductive age—United States, 2008–2012. MMWR Morb Mortal Wkly Rep 64 (2015), 37–41.
29. Yazdy, M.M., Desai, R.J., Brogly, S.B., Prescription opioids in pregnancy and birth outcomes: a review of the literature. J Pediatr Genet 4 (2015), 56–70.
30. Warren, M.D., Miller, A.M., Traylor, J., et al. Centers for Disease Control and Prevention. Implementation of a statewide surveillance system for neonatal abstinence syndrome - Tennessee, 2013. MMWR Morb Mortal Wkly Rep 64 (2015), 125–128.
31. Cicero, T.J., Ellis, M.S., Harney, J., Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med 373 (2015), 1789–1790.
32. Gomes, T., Juurlink, D.N., Opioid use and overdose: what we've learned in Ontario. Healthc Q 18 (2016), 8–11.
33. Jansson, L.M., Velez, M., Neonatal abstinence syndrome. Curr Opin Pediatr 24 (2012), 252–258.
34. Krans, E.E., Cochran, G., Bogen, D.L., Caring for opioid-dependent pregnant women: prenatal and postpartum care considerations. Clin Obstet Gynecol 58 (2015), 370–379.
35. Jumah, N.A., Rural, pregnant, and opioid dependent: a systematic review. Subst Abuse 10 (2016), 35–41.
36. El Marroun, H., Tiemeier, H., Jaddoe, V.W., et al. Demographic, emotional and social determinants of cannabis use in early pregnancy: the Generation R study. Drug Alcohol Depend 98 (2008), 218–226.
37. Passey, M.E., Sanson-Fisher, R.W., D'Este, C.A., et al. Tobacco, alcohol and cannabis use during pregnancy: clustering of risks. Drug Alcohol Depend 134 (2014), 44–50.
38. Bell, R., Rankin, J., Glinianaia, S., Pless-Mulloli, T., Perinatal and Infant Health Information: A scoping study. Northern & Yorkshire Public Health Observatory, Wolfson Research Institute, University of DurhamQueen's Campus, University of Boulevard, Stockton on Tees, UK, 2001.
39. Petersen Williams, P., Jordaan, E., Mathews, C., et al. Alcohol and other drug use during pregnancy among women attending midwife obstetric units in the Cape Metropole, South Africa. Adv Prev Med, 2014, 2014, 871427.
40. Abbott, P., Chase, D., Culture and substance abuse: impact of culture affects approach to treatment. Psychiatric Times 25 (2008), 43–46.
41. Lester, B.M., Andreozzi, L., Appiah, L., Substance use during pregnancy: time for policy to catch up with research. Harm Reduct J, 1, 2004, 5.
42. Matthews, A., Li, C.C., Aranda, F., et al. The influence of acculturation on substance use behaviors among Latina sexual minority women: the mediating role of discrimination. Subst Use Misuse 49 (2014), 1888–1898.
43. Wickstrom, R., Effects of nicotine during pregnancy: human and experimental evidence. Curr Neuropharmacol 5 (2007), 213–222.
44. Cnattingius, S., The epidemiology of smoking during pregnancy: smoking prevalence, maternal characteristics, and pregnancy outcomes. Nicotine Tob Res 6:Suppl 2 (2004), S125–40.
45. Chalmers, B., Dzakpasu, S., Heaman, M., et al. The Canadian maternity experiences survey: an overview of findings. J Obstet Gynaecol Can 30 (2008), 217–228.
46. Centers for Disease Control and Prevention, PRAMS and smoking data tables. 2011, Centers for Disease Control and Prevention, Atlanta, GA Available at: https://www.cdc.gov/prams/data-tobaccotables.htm, Accessed date 31 July 2017.
47. Forray, A., Merry, B., Lin, H., et al. Perinatal substance use: a prospective evaluation of abstinence and relapse. Drug Alcohol Depend 150 (2015), 147–155.
48. Bobo, J.K., Klepinger, D.H., Dong, F.B., Changes in the prevalence of alcohol use during pregnancy among recent and at-risk drinkers in the NLSY cohort. J Womens Health (Larchmt) 15 (2006), 1061–1070.
49. Anderson, A.E., Hure, A.J., Forder, P.M., et al. Risky drinking patterns are being continued into pregnancy: a prospective cohort study. PLoS ONE, 9, 2014, e86171.
50. Substance Abuse and Mental Health Services Administration, Results from the 2012 national survey on drug use and health: summary of national findings. 2013, Substance Abuse and Mental Health Services Administration, Rockville, MD Available at: https://www.samhsa.gov/data/sites/default/files/NSDUHresults2012/NSDUHresults2012.pdf, Accessed date 31 July 2017.
51. Vesga-Lopez, O., Blanco, C., Keyes, K., et al. Psychiatric disorders in pregnant and postpartum women in the United States. Arch Gen Psychiatry 65 (2008), 805–815.
52. Liyanage, V.R., Curtis, K., Zachariah, R.M., et al. Overview of the genetic basis and epigenetic mechanisms that contribute to FASD pathobiology. Curr Top Med Chem 17 (2017), 808–828.
53. Cook, J.L., Green, C.R., Lilley, C.M., et al. Fetal alcohol spectrum disorder: a guideline for diagnosis across the lifespan. CMAJ 188 (2016), 191–197.
54. Carson, G., Cox, L.V., Crane, J., et al. Alcohol use and pregnancy consensus clinical guidelines. J Obstet Gynaecol Can 32 (2010), S1–31.
55. Public Health Agency of Canada, Fetal alcohol spectrum disorder (FASD). 2017, Public Health Agency of Canada;, Ottawa Available at: https://www.canada.ca/en/public-health/services/diseases/fetal-alcohol-spectrum-disorder.html, Accessed date 31 July 2017.
56. Flak, A.L., Su, S., Bertrand, J., et al. The association of mild, moderate, and binge prenatal alcohol exposure and child neuropsychological outcomes: a meta-analysis. Alcohol Clin Exp Res 38 (2014), 214–226.
57. Patrick, S.W., Schumacher, R.E., Benneyworth, B.D., et al. Neonatal abstinence syndrome and associated health care expenditures: United States, 2000–2009. JAMA 307 (2012), 1934–1940.
58. Substance Abuse and Mental Health Services Administration, Results from the 2005 national survey on drug use and health: national findings. 2006, Substance Abuse and Mental Health Services Administration, Rockville, MD Available at: http://www.dpft.org/resources/NSDUHresults2005.pdf, Accessed date 31 July 2017.
59. Substance Abuse and Mental Health Services Administration, Results from the 2013 national survey on drug use and health: summary of national findings. 2014, Substance Abuse and Mental Health Services Administration, Rockville, MD Available at: https://www.samhsa.gov/data/sites/default/files/NSDUHresultsPDFWHTML2013/Web/NSDUHresults2013.pdf, Accessed date 31 July 2017.
60. Terplan, M., Smith, E.J., Kozloski, M.J., et al. Methamphetamine use among pregnant women. Obstet Gynecol 113 (2009), 1285–1291.
61. Hill, M., Reed, K., Pregnancy, breast-feeding, and marijuana: a review article. Obstet Gynecol Surv 68 (2013), 710–718.
62. Moore, D.G., Turner, J.D., Parrott, A.C., et al. During pregnancy, recreational drug-using women stop taking ecstasy (3,4-methylenedioxy-N-methylamphetamine) and reduce alcohol consumption, but continue to smoke tobacco and cannabis: initial findings from the Development and Infancy Study. J Psychopharmacol 24 (2010), 1403–1410.
63. Volkow, N.D., Compton, W.M., Wargo, E.M., The risks of marijuana use during pregnancy. JAMA 317 (2017), 129–130.
64. Buchi, K.F., Zone, S., Langheinrich, K., et al. Changing prevalence of prenatal substance abuse in Utah. Obstet Gynecol 102 (2003), 27–30.
65. Porath-Waller, A.J., Clearing the Smoke on Cannabis: Maternal Cannabis Use during Pregnancy – An Update. Canadian Centre on Substance Abuse; Available at: http://ccsa.ca/Resource%20Library/CCSA-Cannabis-Maternal-Use-Pregnancy-Report-2015-en.pdf, 2015, Accessed date 23 August 2017.
66. Jaques, S.C., Kingsbury, A., Henshcke, P., et al. Cannabis, the pregnant woman and her child: weeding out the myths. J Perinatol 34 (2014), 417–424.
67. Williamson, S., Jacobson, L., Skeoch, C., et al. Prevalence of maternal drug misuse by meconium analysis. Arch Dis Child 88 (2003), 17–21.
68. Lester, B.M., ElSohly, M., Wright, L.L., et al. The Maternal Lifestyle Study: drug use by meconium toxicology and maternal self-report. Pediatrics 107 (2001), 309–317.
69. American College of Obstetricians, Gynecologists Committee on Obstetric Practice, Committee opinion No. 637: marijuana use during pregnancy and lactation. Obstet Gynecol 126 (2015), 234–238.
70. Stone, R., Pregnant women and substance use: fear, stigma, and barriers to care. Health Justice, 3, 2015, 2.
71. Bhuvaneswar, C.G., Chang, G., Epstein, L.A., et al. Cocaine and opioid use during pregnancy: prevalence and management. Prim Care Companion J Clin Psychiatry 10 (2008), 59–65.
72. National Institute on Drug Abuse, National pregnancy. NIDA Notes National Institute on Drug Abuse (NIDA) Notes; 12 (1); Available at: https://archives.drugabuse.gov/NIDA_Notes/NNVol12N1/Survey.html, 1997.
73. Wouldes, T.A., LaGasse, L.L., Derauf, C., et al. Co-morbidity of substance use disorder and psychopathology in women who use methamphetamine during pregnancy in the US and New Zealand. Drug Alcohol Depend 127 (2013), 101–107.
74. Bateman, B.T., Hernandez-Diaz, S., Rathmell, J.P., et al. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology 120 (2014), 1216–1224.
75. Bauer, C.R., Shankaran, S., Bada, H.S., et al. The Maternal Lifestyle Study: drug exposure during pregnancy and short-term maternal outcomes. Am J Obstet Gynecol 186 (2002), 487–495.
76. Pichini, S., Puig, C., Zuccaro, P., et al. Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: preliminary results of the “Meconium Project. Forensic Sci Int 153 (2005), 59–65.
77. Dyk, J., Ramanjam, V., Church, P., et al. Maternal methamphetamine use in pregnancy and long-term neurodevelopmental and behavioral deficits in children. J Popul Ther Clin Pharmacol 21 (2014), e185–96.
78. Wong, S., Ordean, A., Kahan, M., (Society of Ostetricians and Gynaecologists of Canada). SOGC clinical practice guidelines: substance use in pregnancy: No. 256, April 2011. Int J Gynaecol Obstet 114 (2011), 190–202.
79. Connor, J.P., Gullo, M.J., White, A., et al. Polysubstance use: diagnostic challenges, patterns of use and health. Curr Opin Psychiatry 27 (2014), 269–275.
80. Conway, K.P., Vullo, G.C., Nichter, B., et al. Prevalence and patterns of polysubstance use in a nationally representative sample of 10th graders in the United States. J Adolesc Health 52 (2013), 716–723.
81. Wong, C.F., Silva, K., Kecojevic, A., et al. Coping and emotion regulation profiles as predictors of nonmedical prescription drug and illicit drug use among high-risk young adults. Drug Alcohol Depend 132 (2013), 165–171.
82. Morley, K.I., Lynskey, M.T., Moran, P., et al. Polysubstance use, mental health and high-risk behaviours: results from the 2012 Global Drug Survey. Drug Alcohol Rev 34 (2015), 427–437.
83. Knight, M., Kenyon, S., Brocklehurst, P., (Maternal, Newborn, and Infant Clinical Outcome Review Programme). Saving lives, improving mothers' care - lessons learned to inform future maternity care from the UK and Ireland confidential enquiries into maternal deaths and morbidity 2009-12. 2014, National Perinatal Epidemiology Unit, University of Oxford, Oxford, United Kingdom Available at: https://www.npeu.ox.ac.uk/downloads/files/mbrrace-uk/reports/Saving%20Lives%20Improving%20Mothers%20Care%20report%202014%20Full.pdf, Accessed date 31 July 2017.
84. Knight, M., Tuffnell, D., Kenyon, S., et al. (Maternal, Newborn, and Infant Clinical Outcome Review Programme). Saving lives, improving mothers' care - surveillance of maternal deaths in the UK 2011-13 and lessons learned to inform maternity care from the UK and Ireland confidential enquiries into maternal deaths and Morbidity 2009-13. 2015, National Perinatal Epidemiology Unit, University of Oxford, Oxford, United Kingdom Available at: https://www.npeu.ox.ac.uk/downloads/files/mbrrace-uk/reports/MBRRACE-UK%20Maternal%20Report%202015.pdf, Accessed date 31 July 2017.
85. Centers for Disease Control and Prevention, Persons who use drugs (PWUD). 2016, Centers for Disease Control and Prevention, Atlanta, GA Available at: https://www.cdc.gov/pwud/, Accessed date 31 July 2017.
86. McDonald, S.W., Hicks, M., Rasmussen, C., et al. Characteristics of women who consume alcohol before and after pregnancy recognition in a Canadian sample: a prospective cohort study. Alcohol Clin Exp Res 38 (2014), 3008–3016.
87. Powers, J.R., McDermott, L.J., Loxton, D.J., et al. A prospective study of prevalence and predictors of concurrent alcohol and tobacco use during pregnancy. Matern Child Health J 17 (2013), 76–84.
88. Substance Abuse and Mental Health Services, Substance abuse treament: addressing the specific needs of women. A treatment improvement protocol (TIP) 51. 2015, Substance Abuse and Mental Health Services Administration, Rockville, MD Available at: https://store.samhsa.gov/shin/content//SMA15-4426/SMA15-4426.pdf, Accessed date 31 July 2017.